



## **Development of novel aptamer-functionalized liposomes for** oral cancer therapy

## Jéssica Lopes-Nunes<sup>1</sup>, Paula A. Oliveira<sup>2</sup>, Carla Cruz<sup>1</sup>

<sup>1</sup>CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; <sup>2</sup>Centro de Investigação e Tecnologias

Agroambientais e Biológicas (CITAB), Inov4Agro, Universidade de Trás os Montes e Alto Douro (UTAD), Quinta de Prados, 5000-801 Vila Real, Portugal


## Methodology Introduction Conventional anticancer therapies present low specificity, leading to several secondary **Biological** Liposomes Liposomes *Pharmaceuticals* **2021**, *14*(7), 671 **Characterization Evaluation Synthesis** AS1411 is a G4 aptamer able to recognize nucleolin and is being used as an agent for anticancer drug delivery.

AS1411 derivatives have been proposed, with improved toxicity and high affinity to nucleolin.

effects.

**AIM:** To synthesize AS1411 derivatives-functionalized liposomes to improve the selectivity of Imiquimod and  $C_8$  into oral cancer cells.









Figure 1. Dynamic light scattering size distribution of blank liposomes (red), AS1411functionalized liposomes (blue), AT11-functionalized liposomes (green) or AT11-B0 functionalized liposomes (black) in (A) buffer solution (PBS), (B) with C<sub>8</sub> or (C) with Imiquimod (IQ) encapsulated. (D) Transmission electronic microscopy images of the liposomes.

PE	PBS	1.253	$139.3 \pm 2.$	0.436	$150.5 \pm 0.306$
	C <sub>8</sub>	134.9 ± 0.827	153.2 ± 1.	050 145.0 ± 0.666	$140. \pm 0.700$
	Imiquimod	$136.0 \pm 0.702$	$150.6 \pm 1.4$	498 144.2 ± 0.503	313.1 ± 25.53
- -					
В	PDI	Blank Liposome	AS1411 Liposomo		AT11-B0 Liposome
	PBS	0.284 ± 0.020	$0.189 \pm 0.0$	0.357 ± 0.016	$0.133 \pm 0.014$
	C <sub>8</sub>	0.173 ± 0.033	$0.165 \pm 0.0$	0.138 ± 0.003	$0.122 \pm 0.024$
	Imiquimod	0.134 ± 0.013	0.127 ± 0.0	0.138 ± 0.003	$0.541 \pm 0.095$
C	% Functionalization yields		AS1411 Liposome	AT11 Liposome	AT11-B0 Liposome
	C <sub>8</sub>		85.83%	74.45%	79.26%
	Imiquimod		87.67%	64.43%	85.64%

Figure 2. (A) Hydrodynamic size, and (B) polydispersity index (PDI) of the different liposomes. (C) Functionalization yields of liposomes with the aptamers.

Figure 4. Confocal images of UPCI-SCC-154 cells (A) without or (B) with anti-nucleolin antibody (shown in red) incubation. Cell nuclei are stained with Hoechst 33342 (blue).





- Liposomes with sizes up to 200 nm, polydispersity index below 0.4 and functionalization yields up to 85% were obtained.
- ✓ UPCI-SCC-154 cells express nucleolin in their surface.
- ✓ Through the functionalization of liposomes with the AS1411 derivatives we expect to improve the selectivity of Imiquimod and C<sub>8</sub> into oral cancer cells (UPCI-SCC-154 cell line) and to decrease the toxicity in normal epithelial cells (Het-1A cell line).



## The 7th International Electronic Conference on Medicinal Chemistry 01–30 NOVEMBER 2021 ONLINE